Polymer conjugates: nanosized medicines for treating cancer

Area of Science:

• Polymer Chemistry
• Biomedical Sciences
• Nanomedicine

Background:

• Interdisciplinary research combines polymer chemistry and biomedical sciences.
• Development of polymer-based nanomedicines for cancer diagnosis and treatment.
• Two main categories: polymer-protein and polymer-drug conjugates for intravenous administration.

Purpose of the Study:

• To introduce polymer-based nanomedicines for cancer care.
• To describe the design and function of polymer-protein and polymer-drug conjugates.
• To highlight the clinical applications and future potential of these constructs.

Main Methods:

• Polymer conjugation to proteins to reduce immunogenicity, prolong half-life, and enhance stability.
• Polymer-drug conjugation for tumor targeting via the enhanced permeability and retention (EPR) effect.
• Lysosomotropic drug delivery following endocytic capture at the cellular level.

Main Results:

• Clinical success of polymer-protein conjugates (PEGylated enzymes, cytokines).
• Promising clinical trial results for polymer-bound chemotherapy (doxorubicin, paclitaxel, camptothecins).
• Foundation laid for second-generation constructs with targeted anticancer agents and combination therapies.

Conclusions:

• Polymer-based nanomedicines represent a significant advancement in cancer therapy.
• These constructs offer improved drug delivery, targeting, and stability.
• Future developments focus on targeted agents and combination therapies for enhanced efficacy.